Original Article
Brief Report
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
N Engl J Med 2008; 358:2698-2703June 19, 2008
- Abstract
We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.
Media in This Article
Figure 1
PET Scans Obtained before T-Cell Infusion and 2 Months after Infusion.Figure 2
Persistence of Transferred NY-ESO-1–Specific CD4+ T-Cell Clones In Vivo.Article Activity
- Article
CD8+ cytotoxic T cells can be harvested from a patient with cancer, expanded in vitro, selected for specificity against a tumor-associated antigen, and infused back into the patient. Such autologous T cells have been shown in clinical trials to have a beneficial effect in some patients with cancer.1-5 The cytotoxic antitumor effect of CD8+ T cells depends on CD4+ T cells, which provide CD8+ T cells with growth factors such as interleukin-2 and can mediate the destruction of tumor cells either directly or indirectly.5-8 Growth factors such as interleukin-2 can act in an autocrine manner, which in principle would allow an infusion of CD4+ T cells to proliferate in the patient and stimulate endogenous antitumor CD8+ T cells. Until recently, however, a means of isolating and expanding antitumor CD4+ T cells in numbers sufficient for cellular therapy has not been feasible. The identification of HLA class II–restricted epitopes in tumor-associated antigens such as NY-ESO-1 and tyrosinase and the development of methods for the isolation and expansion of CD4+ T cells in vitro gave us the opportunity to implement a clinical trial to evaluate the safety, in vivo persistence, and antitumor efficacy of autologous CD4+ T-cell clones for the treatment of metastatic melanoma. We describe a patient with refractory metastatic melanoma who had a long-term complete remission after receiving autologous NY-ESO-1–specific CD4+ T-cell clones.
Case Report
The patient was 52 years old when he presented with recurrent melanoma and pulmonary and left iliac and inguinal metastases. His tumor had not responded to high-dose interferon alfa, four cycles of high-dose interleukin-2, and local excision. Baseline staging with magnetic resonance imaging of the brain and computed tomography (CT) of the chest, abdomen, and pelvis showed metastatic disease in the posterior right pleura, right hilum, and left iliac region. There were no central nervous system metastases. Positron-emission tomography (PET) of the entire body revealed no other sites of uptake.
Immunohistochemical analysis that was performed on a biopsy specimen of the inguinal tumor revealed uniform expression of melanoma antigen recognized by T cells (MART-1, also called melanoma tumor antigen [MelanA]), 3+ staining of melanoma antigen 3 (MAGE-3), 3+ staining of NY-ESO-1, and no detectable glycoprotein 100. The patient was enrolled in a clinical trial of autologous T-cell therapy for melanoma at the Fred Hutchinson Cancer Research Center in Seattle (protocol 1585). The study was approved by the institutional review board, and the patient provided written informed consent.
Peripheral-blood mononuclear cells were collected by leukopheresis, and T cells in the harvest were cultured. Since the patient's HLA genotype included the HLA-DOB1*0401 allele, CD4+ T-cell clones targeting the DPB1*0401-restricted epitope of a peptide derived from NY-ESO-1 were isolated from the culture and expanded for cellular therapy. In vitro, these clones responded to the NY-ESO-1 peptide by producing interleukin-2 and interferon-γ. During a 2-hour period, the patient received a single infusion of 3.3×109 clonal CD4+ T cells per square meter of body-surface area, totaling 5 billion T cells. No preinfusion conditioning or postinfusion interleukin-2 was administered.
Transient lymphopenia, low-grade fever (maximum temperature, <38.5°C), and myalgia, all consistent with cytokine release,3 developed and resolved within 3 days after the infusion. There were no serious adverse events, according to the Common Toxicity Criteria of the National Cancer Institute. Two months after the infusion, restaging PET and CT scans revealed complete resolution of pulmonary and nodal disease; there was no evidence of abnormal fluorodeoxyglucose uptake and no other radiographic or clinical evidence of disease (Figure 1Figure 1
PET Scans Obtained before T-Cell Infusion and 2 Months after Infusion.). The patient remained disease-free 2 years later.Methods
Generation of Antigen-Specific CD4+ T-Cell Clones
Antigen-specific CD4+ T-cell clones were generated in a manner similar to that for CD8+ T cells described previously.3,9 Briefly, autologous monocyte-derived dendritic cells were pulsed with 40 μg of the NY-ESO-1 peptide SLLMWITQCFLPVF10 per milliliter and cocultured with the patient's T cells at a ratio of 10:1 (T cells:dendritic cells). Interleukin-2 (12.5 IU per milliliter) and interleukin-7 (10 ng per milliliter) were added every 3 days to maintain the growth of activated antigen-specific T cells. One week later, the T cells were restimulated with peptide-pulsed autologous mononuclear cells. One week after the second stimulation, T cells with specific reactivity against the NY-ESO-1 peptide were harvested and cloned at limiting dilution in the presence of irradiated feeder cells (mononuclear cells plus Epstein–Barr virus–transformed B cells), a monoclonal anti-CD3 antibody, and interleukin-2. Clones that showed a specific proliferative response to the NY-ESO-1 peptide in a thymidine incorporation assay were expanded in vitro. A total of four NY-ESO-1–specific CD4+ T-cell clones were generated from the patient. The clone that was selected for infusion could be expanded by a factor of 3000 to 5000 during a period of 18 days with the use of established methods.11 Reactivity against NY-ESO-1 was confirmed after expansion by performing assays to detect antigen-specific proliferation and the release of interferon-γ (for details, see the Supplementary Appendix, available with the full text of this article at www.nejm.org).
Detection of Antibodies against Tumor-Associated Antigens
An enzyme-linked immunosorbent assay was used to detect IgG antibodies against recombinant full-length NY-ESO-1, MAGE-3, and MART-1 proteins (1 μg per milliliter), as described previously.12 Reciprocal titers were extrapolated from serial dilutions, and titers of more than 100 were considered to be reactive. Specificity was determined by comparing reactivity with that of control antigens.
Assay for Antigen-Specific Responses
To evaluate the postinfusion T-cell responses to a panel of melanoma antigens, RNA-transfected autologous dendritic cells were used as stimulator cells in enzyme-linked immunospot (ELISPOT) assays. Melanoma antigens MART-1, glycoprotein 100, NY-ESO-1, and MAGE-3 were subcloned into the pGEM4Z vector, flanked by the signal sequence from lysosomal-associated membrane protein 1 (LAMP-1) to facilitate antigen sorting to both class I and class II antigen-presentation pathways (for details, see the Supplementary Appendix).13 For the inteferon-γ ELISPOT assay, the patient's mononuclear cells were cocultivated with RNA-transfected dendritic cells at a ratio of 2:1 in triplicate filter wells. After overnight incubation, the plates were treated with a biotinylated anti–interferon-γ-detection antibody, clone 7B61 (Mabtech). Streptavidin HRP (Pharmingen) was added and developed to produce a color reaction with the use of the Vectastain AEC substrate kit (Vector Laboratories). Each spot on the filter well represented a single antigen-stimulated T cell. Spots were enumerated and the antigen-specific T-cell frequency was calculated as a fraction of the input number of mononuclear cells (see the Supplementary Appendix for details).
T-Cell Tracking by Quantitative PCR
We detected cells of the NY-ESO-1–specific CD4+ T-cell clone in the patient's blood using primers flanking the CDR3 region of the T-cell receptor of the clone. Genomic DNA from mononuclear cells was harvested and used as a template for a quantitative real-time polymerase-chain-reaction (PCR) assay. The frequency of the cells was determined by reconciling the melting temperature of the sample's reaction with that obtained from standards titrated with known frequencies of the CD4+ T-cell clone. This assay can detect a T-cell clone in peripheral blood at a sensitivity of 1:100,000 cells.
Results
Persistence of the CD4+ T-Cell Clone
The persistence of the infused NY-ESO-1–specific CD4+ T-cell clone in vivo was evaluated with the use of a quantitative PCR assay that can detect the clone-specific CDR3 region in samples of mononuclear cells. The T-cell clone was undetectable in preinfusion samples from the patient. After infusion, however, there was a rapid rise in the frequency of cells of the clone: they constituted almost 2.0% of all peripheral-blood mononuclear cells on day 3 and remained detectable in the patient's blood for more than 80 days (Figure 2Figure 2
Persistence of Transferred NY-ESO-1–Specific CD4+ T-Cell Clones In Vivo.). During this time, the frequency of cells of the clone fluctuated between 0.7 and 3.0% of the total number of mononuclear cells.Clinical Evaluation
CT and PET scans obtained 2 months after the T-cell infusion revealed no evidence of disease, and follow-up after 22 months showed no evidence of recurrence (Figure 1). At the time of the last contact with the patient, 26 months after the T-cell infusion, he had received no other treatment and had normal function, with a Karnofsky performance status of 90 to 100%. There were no detectable acute or long-term autoimmune-related toxic effects (e.g., dermatitis, vitiligo, uveitis, and orchitis).
T-Cell Responses to Unrelated Antigens
Even though only 50 to 75% of the tumor cells expressed NY-ESO-1, the entire tumor regressed after infusion of the NY-ESO-1–specific CD4+ T-cell clone. This inconsistency led us to postulate that the infused clone induced an immune response that was broader than expected. To test this hypothesis, we evaluated T-cell responses to two other melanoma-associated antigens that were expressed by the patient's tumor, MART-1 and MAGE-3. Using autologous dendritic cells that were engineered by RNA transfection to express these antigens, we could detect T cells in the patient's blood that responded in vitro to MART-1 or MAGE-3. These T cells were undetectable before the infusion of NY-ESO-1–specific CD4+ T cells but became detectable at a time that coincided with regression of the tumor and persisted for at least 3 months. We found no evidence of T cells that could respond to glycoprotein 100, which was poorly expressed by the tumor (Figure 3Figure 3
Augmentation of T-Cell Responses to Melanoma-Associated Tumor Antigens.).Discussion
We describe an in vitro method for the development of CD4+ T-cell clones with specificity for a tumor antigen and the use of one such clone for the treatment of a patient with metastatic melanoma. Development of the method has been difficult, in part because of the paucity of well-defined immunogenic HLA class II–restricted epitopes of tumor antigens and also because of the difficulty in isolating and expanding CD4+ T-cell clones to obtain numbers sufficient for clinical use. The HLA-DP4–restricted peptide epitope of the melanoma-associated cancer–testis antigen NY-ESO-1 is one of the most immunogenic tumor antigens10,14 and can elicit responses by CD4+ T cells from patients with cancer who have been immunized with NY-ESO-1.15,16
Using the NY-ESO-1 peptide, we succeeded in generating NY-ESO-1–specific CD4+ T cells from the blood of an unimmunized patient with metastatic melanoma. We were able to expand these cells to several billion and use them to treat the patient. No exogenous cytokines were administered because these CD4+ T cells, when stimulated in vitro by the NY-ESO-1 antigen, produce autocrine-active interleukin-2. After infusion of the cells, influenza-like symptoms and lymphopenia, signs of a cytokine release syndrome, developed. In contrast to transferred CD8+ T cells, which survive only briefly (<20 days) in vivo in the absence of exogenous cytokine,1,3 the CD4+ T-cell clones that we administered without any cytokine treatment were detectable in the patient's blood for at least 3 months. Therefore, the possibility that in vitro–derived and clonally expanded T cells were functionally exhausted17 was not substantiated by our results.
Our studies and those performed by others have shown that immunotherapy with antigen-specific T cells can eliminate tumor cells that express the corresponding antigen, but it can also allow the outgrowth of antigen-loss tumor variants.1,3 The target antigen in our case, NY-ESO-1, was not uniformly expressed by the cells of the patient's melanoma, yet the tumor regressed completely. We postulate that the complete regression of the tumor can be attributed in part to responses by the patient's immune system to other antigens displayed by the tumor. This additional response could have come about through antigens in apoptotic bodies that were released from killed tumor cells. When collected and processed by antigen-presenting cells, these antigens probably activated a variety of T cells, thereby broadening the immune response, a process referred to as antigen spreading.18,19 The delay of days to weeks in the development of these additional responses is consistent with antigen spreading (Figure 3).
The fact that T cells against glycoprotein 100, an antigen that was not expressed by the melanoma, were undetectable indicates the selectivity of the antitumor immune responses. It is also possible that the reduction in the tumor burden relieved immunosuppression in the tumor microenvironment caused by inhibitory cytokines and regulatory T cells, thereby contributing to the broadened T-cell response. IgG antibodies against NY-ESO-1 were detectable in plasma samples from the patient before infusion of the T-cell clone and remained unchanged in titer after the infusion. The presence of antibodies against NY-ESO-1 is associated with an increased likelihood that NY-ESO-1–specific CD4+ and CD8+ T-cell responses will be generated ex vivo.14,20 Antibodies against MAGE-3 and MART-1 were undetectable before the T-cell infusion and afterward for up to 87 days (Figure 1 in the Supplementary Appendix). The lack of an increase in the titers of antibodies against melanoma antigens despite the appearance of CD4+ T cells against these antigens suggests that the production of such antibodies is independent of T cells.
In summary, we showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of his tumor. These findings support further clinical studies of antigen-specific CD4+ T cells in the treatment of malignant disease.
Supported in part by grants from the National Institutes of Health (CA12823 and CA1047113) and the General Clinical Research Center (M01-RR-00037) and by the Edson Foundation and the Damon Runyon Cancer Research Foundation. Dr. Yee is a recipient of the Clinical Scientist Award in Translational Research from the Burroughs Wellcome Fund.
No potential conflict of interest relevant to this article was reported.
We thank Yong Qing Li and Kaye Dowdy for their technical assistance, Lisa Schirmer for assistance in clinical research support, and Sandra Gan for logistical support.
Source Information
From the Fred Hutchinson Cancer Research Center (N.N.H., H.W., J.C., D.W.H., J.Z.R., R.R., C.Y.) and the University of Washington (J.A.T., C.Y.) — both in Seattle; and the Ludwig Institute for Cancer Research (New York Branch), Memorial Sloan-Kettering Cancer Center, New York (A.J., S.G.).
Address reprint requests to Dr. Yee at the Fred Hutchinson Cancer Research Center, Room D3-100, 1100 Fairview Ave. N., Seattle, WA 98109, or at cyee@fhcrc.org.
- References
References
1
Mackensen A ,Meidenbauer N ,Vogl S ,Laumer M ,Berger J ,Andreesen R . Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006;24:5060-5069
CrossRef | Web of Science | Medline2
Mitchell MS ,Darrah D ,Yeung D , et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 2002;20:1075-1086
CrossRef | Web of Science | Medline3
Yee C ,Thompson JA ,Byrd D , et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-16173
CrossRef | Web of Science | Medline4
Dudley ME ,Wunderlich JR ,Robbins PF , et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854
CrossRef | Web of Science | Medline5
Greenberg PD . Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355
CrossRef | Web of Science | Medline6
Romerdahl CA ,Kripke ML . Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. Cancer Res 1988;48:2325-2328
Web of Science | Medline7
Hung K ,Hayashi R ,Lafond-Walker A ,Lowenstein C ,Pardoll D ,Levitsky H . The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368
CrossRef | Web of Science | Medline8
Greenberg PD ,Kern DE ,Cheever MA . Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells: tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985;161:1122-1134
CrossRef | Web of Science | Medline9
Li Y ,Bleakley M ,Yee C . IL-21 influences the frequency, phenotype, and affinity of the CD8 T cell response. J Immunol 2005;175:2261-2269
Web of Science | Medline10
Zeng G ,Li Y ,El-Gamil M , et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002;62:3630-3635
Web of Science | Medline11
Riddell SR ,Greenberg PD . The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990;128:189-201
CrossRef | Web of Science | Medline12
Stockert E ,Jager E ,Chen YT , et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-1354
CrossRef | Web of Science | Medline13
Liao X ,Li Y ,Bonini C , et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 2004;9:757-764
CrossRef | Web of Science | Medline14
Gnjatic S ,Atanackovic D ,Jager E , et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A 2003;100:8862-8867
CrossRef | Web of Science | Medline15
Odunsi K ,Qian F ,Matsuzaki J , et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007;104:12837-12842
CrossRef | Web of Science | Medline16
Khong HT ,Yang JC ,Topalian SL , et al. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 2004;27:472-477
CrossRef | Web of Science | Medline17
Gattinoni L ,Powell DJ Jr ,Rosenberg SA ,Restifo NP . Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-393
CrossRef | Web of Science | Medline18
Nowak AK ,Lake RA ,Marzo AL , et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170:4905-4913
Web of Science | Medline19
Bevan MJ . Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-1288
CrossRef | Web of Science | Medline20
Jager E ,Chen YT ,Drijfhout JW , et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-270
CrossRef | Web of Science | Medline
- Citing Articles (151)
Citing Articles
1
Katie E Lacy, Sophia N Karagiannis, Frank O Nestle. (2012) Immunotherapy for melanoma. Expert Review of Dermatology 7:1, 51-68
CrossRef2
Y Gao, P Whitaker-Dowling, J A Griffin, I Bergman. (2012) Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells. Cancer Gene Therapy
CrossRef3
Harlan Robins, Cindy Desmarais, Jessica Matthis, Robert Livingston, Jessica Andriesen, Helena Reijonen, Christopher Carlson, Gerold Nepom, Cassian Yee, Karen Cerosaletti. (2012) Ultra-sensitive detection of rare T cell clones. Journal of Immunological Methods 375:1-2, 14-19
CrossRef4
Vincenzo Russo, Attilio Bondanza, Fabio Ciceri, Marco Bregni, Claudio Bordignon, Catia Traversari, Chiara Bonini. (2012) A dual role for genetically modified lymphocytes in cancer immunotherapy. Trends in Molecular Medicine
CrossRef5
Camila Ferreira de Souza, Alice Santana Morais, Miriam Galvonas Jasiulionis. (2012) Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases. Dermatology Research and Practice 2012, 1-14
CrossRef6
Norihiko Takahashi, Takayuki Ohkuri, Shigenori Homma, Junya Ohtake, Daiko Wakita, Yuji Togashi, Hidemitsu Kitamura, Satoru Todo, Takashi Nishimura. (2012) First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Science 103:1, 150-153
CrossRef7
Daniela Montagna, Ilaria Turin, Roberta Schiavo, Enrica Montini, Nadia Zaffaroni, Raffaella Villa, Simona Secondino, Ilaria Schiavetto, Laura Caliogna, Franco Locatelli, Virginia Libri, Andrea Pession, Roberto Tonelli, Rita Maccario, Salvatore Siena, Paolo Pedrazzoli. (2012) Feasibility and safety of adoptive immunotherapy with ex vivo -generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy 14:1, 80-90
CrossRef8
Thomas F. Gajewski. (2012) Cancer immunotherapy. Molecular Oncology
CrossRef9
Caroline J. Voskens, Duane Sewell, Ronna Hertzano, Jennifer DeSanto, Sandra Rollins, Myounghee Lee, Rodney Taylor, Jeffrey Wolf, Mohan Suntharalingam, Brian Gastman, John C. Papadimitriou, Changwan Lu, Ming Tan, Robert Morales, Kevin Cullen, Esteban Celis, Dean Mann, Scott E. Strome. (2012) inducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head & Neckn/a-n/a
CrossRef10
Zhi-Chun Ding, Gang Zhou. (2012) Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects. Clinical and Developmental Immunology 2012, 1-12
CrossRef11
R. D. Aubert, A. O. Kamphorst, S. Sarkar, V. Vezys, S.-J. Ha, D. L. Barber, L. Ye, A. H. Sharpe, G. J. Freeman, R. Ahmed. (2011) Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proceedings of the National Academy of Sciences 108:52, 21182-21187
CrossRef12
Katayoun Rezvani, Agnes S. M. Yong, Stephan Mielke, Bipin N. Savani, Behnam Jafarpour, Rhoda Eniafe, Robert Quan Le, Laura Musse, Carole Boss, Richard Childs, A. John Barrett. (2011) Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunology, Immunotherapy
CrossRef13
Tai-Ming Ko, Wen-Hung Chung, Chun-Yu Wei, Han-Yu Shih, Jung-Kuei Chen, Chia-Hsien Lin, Yuan-Tsong Chen, Shuen-Iu Hung. (2011) Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. Journal of Allergy and Clinical Immunology 128:6, 1266-1276.e11
CrossRef14
Fernanda V. Castro, Mariam Al-Muftah, Kate Mulryan, Hui-Rong Jiang, Jan-Wouter Drijfhout, Sumia Ali, Andrzej J. Rutkowski, Milena Kalaitsidou, David E. Gilham, Peter L. Stern. (2011) Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. Cancer Immunology, Immunotherapy
CrossRef15
Mark J. Dobrzanski, Kathleen A. Rewers-Felkins, Khaliquzzaman A. Samad, Imelda S. Quinlin, Catherine A. Phillips, William Robinson, David J. Dobrzanski, Stephen E. Wright. (2011) Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunology, Immunotherapy
CrossRef16
Iacopo Petrini, Simone Pacini, Sara Galimberti, Maria R. Taddei, Antonella Romanini, Mario Petrini. (2011) Impaired function of gamma-delta lymphocytes in melanoma patients. European Journal of Clinical Investigation 41:11, 1186-1194
CrossRef17
Theo Nicholaou, Weisan Chen, Ian D. Davis, Heather M. Jackson, Nektaria Dimopoulos, Catherine Barrow, Judy Browning, Duncan MacGregor, David Williams, Wendie Hopkins, Eugene Maraskovsky, Ralph Venhaus, Linda Pan, Eric W. Hoffman, Lloyd J. Old, Jonathan Cebon. (2011) Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™. Cancer Immunology, Immunotherapy 60:11, 1625-1637
CrossRef18
J. Yuan, M. Adamow, B. A. Ginsberg, T. S. Rasalan, E. Ritter, H. F. Gallardo, Y. Xu, E. Pogoriler, S. L. Terzulli, D. Kuk, K. S. Panageas, G. Ritter, M. Sznol, R. Halaban, A. A. Jungbluth, J. P. Allison, L. J. Old, J. D. Wolchok, S. Gnjatic. (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences 108:40, 16723-16728
CrossRef19
SHERRIF F. IBRAHIM, DIVYA SAMBANDAN, DÉSIRÉE RATNER. (2011) Immunotherapy for Cutaneous Malignancy. Dermatologic Surgery 37:10, 1377-1393
CrossRef20
Leodevico L. Ilag. (2011) Immunoglobulin M as a vaccine adjuvant. Medical Hypotheses 77:4, 473-478
CrossRef21
Teofila Seremet, Francis Brasseur, Pierre G. Coulie. (2011) Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy. The Cancer Journal 17:5, 325-330
CrossRef22
S Merims, X Li, B Joe, P Dokouhaki, M Han, R W Childs, Z-Y Wang, V Gupta, M D Minden, L Zhang. (2011) Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. Leukemia 25:9, 1415-1422
CrossRef23
James C. Yang. (2011) Melanoma Vaccines. The Cancer Journal 17:5, 277-282
CrossRef24
Craig L. Slingluff. (2011) The Present and Future of Peptide Vaccines for Cancer. The Cancer Journal 17:5, 343-350
CrossRef25
Sergio A Quezada, Karl S Peggs. (2011) Tumor-reactive CD4 + T cells: plasticity beyond helper and regulatory activities. Immunotherapy 3:8, 915-917
CrossRef26
Cedrik M. Britten, Sylvia Janetzki, Cécile Gouttefangeas, Marij J. P. Welters, Michael Kalos, Christian Ottensmeier, Axel Hoos, Sjoerd H. van der Burg. 2011. T-cell immune monitoring assays to guide the development of new cancer vaccines. , 156-166.
CrossRef27
Antoni Ribas, Adrian Bot. 2011. Introduction: Cancer vaccines—mechanisms and a clinical overview. , 1-8.
CrossRef28
P Pedrazzoli, P Comoli, D Montagna, T Demirer, M Bregni. (2011) Is adoptive T-cell therapy for solid tumors coming of age?. Bone Marrow Transplantation
CrossRef29
Raluca A. Budiu, Gina Mantia-Smaldone, Esther Elishaev, Tianjiao Chu, Julia Thaller, Kathryn McCabe, Diana Lenzner, Robert P. Edwards, Anda M. Vlad. (2011) Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunology, Immunotherapy 60:7, 975-984
CrossRef30
Els M. E. Verdegaal, Marten Visser, Tamara H. Ramwadhdoebé, Caroline E. Minne, Jeanne A. Q. M. J. Steijn, Ellen Kapiteijn, John B. A. G. Haanen, Sjoerd H. Burg, Johan W. R. Nortier, Susanne Osanto. (2011) Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunology, Immunotherapy 60:7, 953-963
CrossRef31
A Balduzzi, G Lucchini, H H Hirsch, S Basso, M Cioni, A Rovelli, A Zincone, M Grimaldi, P Corti, S Bonanomi, A Biondi, F Locatelli, E Biagi, P Comoli. (2011) Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplantation 46:7, 987-992
CrossRef32
Ninke Leffers, Toos Daemen, H Marike Boezen, Kees JM Melief, Hans W Nijman. (2011) Vaccine-based clinical trials in ovarian cancer. Expert Review of Vaccines 10:6, 775-784
CrossRef33
Simon Ausländer, Markus Wieland, Martin Fussenegger. (2011) Smart medication through combination of synthetic biology and cell microencapsulation. Metabolic Engineering
CrossRef34
Else M. Inderberg Suso, Svein Dueland, Anne-Marie Rasmussen, Turid Vetrhus, Steinar Aamdal, Gunnar Kvalheim, Gustav Gaudernack. (2011) hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunology, Immunotherapy 60:6, 809-818
CrossRef35
A. Corthay, K. B. Lorvik, B. Bogen. (2011) Is Secretion of Tumour-specific Antigen Important for Cancer Eradication by CD4+ T Cells? - Implications for Cancer Immunotherapy by Adoptive T Cell Transfer. Scandinavian Journal of Immunology 73:6, 527-530
CrossRef36
Antoni Ribas, Keith T. Flaherty. (2011) BRAF targeted therapy changes the treatment paradigm in melanoma. Nature Reviews Clinical Oncology 8:7, 426-433
CrossRef37
S. Secondino, M. Zecca, L. Licitra, A. Gurrado, I. Schiavetto, P. Bossi, L. Locati, R. Schiavo, S. Basso, F. Baldanti, R. Maccario, F. Locatelli, S. Siena, P. Pedrazzoli, P. Comoli. (2011) T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Annals of Oncology
CrossRef38
Dilan Dissanayake, Matthew A. Gronski, Albert Lin, Alisha R. Elford, Pamela S. Ohashi. (2011) Immunological perspective of self versus tumor antigens: insights from the RIP-gp model. Immunological Reviews 241:1, 164-179
CrossRef39
Sergio A. Quezada, Karl S. Peggs, Tyler R. Simpson, James P. Allison. (2011) Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews 241:1, 104-118
CrossRef40
Michael P Brown. (2011) Do human lymphocyte antigens play a role in the clinical antimelanoma activity of ipilimumab?. Immunotherapy 3:5, 595-599
CrossRef41
David L. A. Figueiredo, Rui C. M. Mamede, Giulio C. Spagnoli, Wilson A. Silva, Marco Zago, Luciano Neder, Achim A. Jungbluth, Fabiano P. Saggioro. (2011) High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head & Neck 33:5, 702-707
CrossRef42
Nathalie Labarriere, Amir Khammari, Francois Lang, Brigitte Dreno. (2011) Is antigen specificity the key to efficient adoptive T-cell therapy?. Immunotherapy 3:4, 495-505
CrossRef43
Marie Bleakley, Stanley R Riddell. (2011) Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunology and Cell Biology 89:3, 396-407
CrossRef44
Anne Rogel, Virginie Vignard, Mathilde Bobinet, Nathalie Labarriere, François Lang. (2011) A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunology, Immunotherapy 60:3, 327-337
CrossRef45
Kevin KH Chow, Stephen Gottschalk. (2011) Cellular immunotherapy for high-grade glioma. Immunotherapy 3:3, 423-434
CrossRef46
David E Gilham. (2011) Effective adoptive T-cell therapy for cancer in the absence of host lymphodepletion. Immunotherapy 3:2, 177-179
CrossRef47
M. J. Goldstein, B. Varghese, J. D. Brody, R. Rajapaksa, H. Kohrt, D. K. Czerwinski, S. Levy, R. Levy. (2011) A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 117:1, 118-127
CrossRef48
Christopher A. Klebanoff, Nicolas Acquavella, Zhiya Yu, Nicholas P. Restifo. (2011) Therapeutic cancer vaccines: are we there yet?. Immunological Reviews 239:1, 27-44
CrossRef49
Erin A. Kimbrel, Shi-Jiang Lu. (2011) Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components. Stem Cells International 2011, 1-11
CrossRef50
Xiao-Tong Song, Meghan E Turnis, Xiaoou Zhou, Wei Zhu, Bang-Xing Hong, Lisa Rollins, Brian Rabinovich, Si-Yi Chen, Cliona M Rooney, Stephen Gottschalk. (2011) A Th1-inducing Adenoviral Vaccine for Boosting Adoptively Transferred T Cells. Molecular Therapy 19:1, 211-217
CrossRef51
Melanie Widenmeyer, Heinrich Griesemann, Stefan Stevanović, Susan Feyerabend, Reinhild Klein, Sebastian Attig, Jörg Hennenlotter, Dorothee Wernet, Dmitri V. Kuprash, Alexei Y. Sazykin, Steve Pascolo, Arnulf Stenzl, Cécile Gouttefangeas, Hans-Georg Rammensee. (2011) Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. International Journal of Cancern/a-n/a
CrossRef52
Christopher Zito, Harriet M. Kluger. (2011) Immunotherapy for metastatic melanoma. Journal of Cellular Biochemistryn/a-n/a
CrossRef53
Renee Vermeij, Ninke Leffers, Baukje-Nynke Hoogeboom, Ineke L. E. Hamming, Rinze Wolf, Anna K.L. Reyners, Barbara H.W. Molmans, Harry Hollema, Joost Bart, Jan W. Drijfhout, Jaap Oostendorp, Ate G.J. van der Zee, Cornelis J. Melief, Sjoerd H. van der Burg, Toos Daemen, Hans W. Nijman. (2011) Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer, a single arm phase II study. International Journal of Cancern/a-n/a
CrossRef54
Jose Lutzky. (2010) New Therapeutic Options in the Medical Management of Advanced Melanoma. Seminars in Cutaneous Medicine and Surgery 29:4, 249-257
CrossRef55
Sung P. Ha, Nicholas D. Klemen, Garrett H. Kinnebrew, Andrew G. Brandmaier, Jon Marsh, Giao Hangoc, Douglas C. Palmer, Nicholas P. Restifo, Kenneth Cornetta, Hal E. Broxmeyer, Christopher E. Touloukian. (2010) Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. Journal of Clinical Investigation 120:12, 4273-4288
CrossRef56
P. Dillon, N. Thomas, N. Sharpless, F. Collichio. (2010) Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Medical Oncology 27:4, 1127-1132
CrossRef57
T. Feuchtinger, K. Opherk, W. A. Bethge, M. S. Topp, F. R. Schuster, E. M. Weissinger, M. Mohty, R. Or, M. Maschan, M. Schumm, K. Hamprecht, R. Handgretinger, P. Lang, H. Einsele. (2010) Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116:20, 4360-4367
CrossRef58
M. O. Butler, S. Ansen, M. Tanaka, O. Imataki, A. Berezovskaya, M. M. Mooney, G. Metzler, M. I. Milstein, L. M. Nadler, N. Hirano. (2010) A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. International Immunology 22:11, 863-873
CrossRef59
Eun Sook Hwang. (2010) This month in APR. Archives of Pharmacal Research 33:11, 1699-1701
CrossRef60
S Mastaglio, M T L Stanghellini, C Bordignon, A Bondanza, F Ciceri, C Bonini. (2010) Progress and prospects: graft-versus-host disease. Gene Therapy 17:11, 1309-1317
CrossRef61
Pouneh Dokouhaki, Mei Han, Betty Joe, Ming Li, Michael R. Johnston, Ming-Sound Tsao, Li Zhang. (2010) Adoptive immunotherapy of cancer using ex vivo expanded human γδ T cells: A new approach. Cancer Letters 297:1, 126-136
CrossRef62
Akshata Udyavar, Terrence L. Geiger. (2010) Rebalancing Immune Specificity and Function in Cancer by T-Cell Receptor Gene Therapy. Archivum Immunologiae et Therapiae Experimentalis 58:5, 335-346
CrossRef63
Paul C. Tumeh, Richard C. Koya, Thinle Chodon, Nicholas A. Graham, Thomas G. Graeber, Begoña Comin-Anduix, Antoni Ribas. (2010) The Impact of Ex Vivo Clinical Grade Activation Protocols on Human T-cell Phenotype and Function for the Generation of Genetically Modified Cells for Adoptive Cell Transfer Therapy. Journal of Immunotherapy 33:8, 759-768
CrossRef64
Marek Jakóbisiak, Jakub Gołąb. (2010) Genetic Modification of T Cells Improves the Effectiveness of Adoptive Tumor Immunotherapy. Archivum Immunologiae et Therapiae Experimentalis 58:5, 347-354
CrossRef65
Margherita Gigante, Elena Ranieri. (2010) Research Highlights. Immunotherapy 2:5, 607-609
CrossRef66
Matthias T Stephan, James J Moon, Soong Ho Um, Anna Bershteyn, Darrell J Irvine. (2010) Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nature Medicine 16:9, 1035-1041
CrossRef67
Marija Pastorcic-Grgic, Bozena Sarcevic, Danijel Dosen, Antonio Juretic, Giulio C. Spagnoli, Marko Grgic. (2010) Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. Head & Neck 32:9, 1178-1184
CrossRef68
P. Sharma. (2010) Cancer immunotherapy: In vivo imaging of adoptively transferred T cells in an immunocompetent host. Proceedings of the National Academy of Sciences 107:32, 13977-13978
CrossRef69
Debora Martorelli, Elena Muraro, Anna Merlo, Riccardo Turrini, Antonio Rosato, Riccardo Dolcetti. (2010) Role of CD4 + Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer. International Reviews of Immunology 29:4, 371-402
CrossRef70
Christian Schütz, Mathias Oelke, Jonathan P Schneck, Andreas Mackensen, Martin Fleck. (2010) Killer artificial antigen-presenting cells: the synthetic embodiment of a ‘guided missile’. Immunotherapy 2:4, 539-550
CrossRef71
Maika Almstedt, Nadja Blagitko-Dorfs, Jesús Duque-Afonso, Julia Karbach, Dietmar Pfeifer, Elke Jäger, Michael Lübbert. (2010) The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leukemia Research 34:7, 899-905
CrossRef72
Mona Karlsson, Per Marits, Kjell Dahl, Tobias Dagöö, Sven Enerbäck, Magnus Thörn, Ola Winqvist. (2010) Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer. Annals of Surgical Oncology 17:7, 1747-1757
CrossRef73
Cassian Yee. (2010) Adoptive Therapy Using Antigen-Specific T-Cell Clones. The Cancer Journal 16:4, 367-373
CrossRef74
Marc Pellegrini, Tak W. Mak. (2010) Tumor immune therapy: Lessons from infection and implications for cancer - Can IL-7 help overcome immune inhibitory networks?. European Journal of Immunology 40:7, 1852-1861
CrossRef75
Dannie Bernard, Michael S Ventresca, Laura A Marshall, Carole Evelegh, Yonghong Wan, Jonathan L Bramson. (2010) Processing of Tumor Antigen Differentially Impacts the Development of Helper and Effector CD4+ T-cell Responses. Molecular Therapy 18:6, 1224-1232
CrossRef76
Richard J. O’Reilly, Tao Dao, Guenther Koehne, David Scheinberg, Ekaterina Doubrovina. (2010) Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Seminars in Immunology 22:3, 162-172
CrossRef77
Jonathan Cebon, Ashley Knights, Lisa Ebert, Heather Jackson, Weisan Chen. (2010) Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. Expert Review of Vaccines 9:6, 617-629
CrossRef78
Peter A. Prieto, Katherine H. Durflinger, John R. Wunderlich, Steven A. Rosenberg, Mark E. Dudley. (2010) Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy. Journal of Immunotherapy 33:5, 547-556
CrossRef79
Cara K Fraser, Michael P Brown, Kerrilyn R Diener, John D Hayball. (2010) Unravelling the complexity of cancer–immune system interplay. Expert Review of Anticancer Therapy 10:6, 917-934
CrossRef80
Daniel E. Speiser, Pedro Romero. (2010) Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Seminars in Immunology 22:3, 144-154
CrossRef81
Malcolm Brenner. (2010) T cell receptors and cancer: gain gives pain. Nature Medicine 16:5, 520-521
CrossRef82
Alastair Matheson. (2010) Five Steps for Structural Reform in Clinical Cancer Research. American Journal of Public Health 100:4, 596-603
CrossRef83
Michel Adamina. (2010) When gene therapy meets adoptive cell therapy: better days ahead for cancer immunotherapy?. Expert Review of Vaccines 9:4, 359-363
CrossRef84
Anne-Marie Rasmussen, Gabriel Borelli, Hanna Julie Hoel, Kari Lislerud, Gustav Gaudernack, Gunnar Kvalheim, Tanja Aarvak. (2010) Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. Journal of Immunological Methods 355:1-2, 52-60
CrossRef85
Weiping Zou, Nicholas P. Restifo. (2010) TH17 cells in tumour immunity and immunotherapy. Nature Reviews Immunology 10:4, 248-256
CrossRef86
Z.-C. Ding, B. R. Blazar, A. L. Mellor, D. H. Munn, G. Zhou. (2010) Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 115:12, 2397-2406
CrossRef87
Y. Xie, A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane, E.-K. M. Kwon, P. Muranski, N. P. Restifo, P. A. Antony. (2010) Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. Journal of Experimental Medicine 207:3, 651-667
CrossRef88
S. A. Quezada, T. R. Simpson, K. S. Peggs, T. Merghoub, J. Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P. A. Antony, N. P. Restifo, J. P. Allison. (2010) Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. Journal of Experimental Medicine 207:3, 637-650
CrossRef89
Anda M. Vlad, Raluca A. Budiu, Diana E. Lenzner, Yun Wang, Julia A. Thaller, Kelly Colonello, Peggy A. Crowley-Nowick, Joseph L. Kelley, Fredric V. Price, Robert P. Edwards. (2010) A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunology, Immunotherapy 59:2, 293-301
CrossRef90
Yolanda Nesbeth, Jose R. Conejo-Garcia. (2010) Harnessing the Effect of Adoptively Transferred Tumor-Reactive T Cells on Endogenous (Host-Derived) Antitumor Immunity. Clinical and Developmental Immunology 2010, 1-11
CrossRef91
Stephen E. Wright, Kathleen A. Rewers-Felkins, Imelda S. Quinlin, Catherine A. Phillips, Mary Townsend, Ramila Philip, Paul Zorsky, Panpit Klug, Lijun Dai, Mohammad Hussain, Aabu A. Thomas, Chithraleka Sundaramurthy. (2010) Number of Treatment Cycles Influences Development of Cytotoxic T Cells in Metastatic Breast Cancer Patients – A Phase I/II Study. Immunological Investigations 39:6, 570-586
CrossRef92
Toshiki Ochi, Hiroshi Fujiwara, Masaki Yasukawa. (2010) Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia. Journal of Biomedicine and Biotechnology 2010, 1-11
CrossRef93
Claudia Papewalis, Margret Ehlers, Matthias Schott. (2010) Advances in Cellular Therapy for the Treatment of Thyroid Cancer. Journal of Oncology 2010, 1-11
CrossRef94
Renee Vermeij, Toos Daemen, Geertruida H. de Bock, Pauline de Graeff, Ninke Leffers, Annechien Lambeck, Klaske A. ten Hoor, Harry Hollema, Ate G. J. van der Zee, Hans W. Nijman. (2010) Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer. Clinical and Developmental Immunology 2010, 1-8
CrossRef95
Yuri Kogan, Urszula Fory, Ofir Shukron, Natalie Kronik, Zvia Agur. (2010) Cellular Immunotherapy for High Grade Gliomas: Mathematical Analysis Deriving Efficacious Infusion Rates Based on Patient Requirements. SIAM Journal on Applied Mathematics 70:6, 1953
CrossRef96
Jonathan Treisman, Nina Garlie. (2010) Systemic Therapy for Cutaneous Melanoma. Clinics in Plastic Surgery 37:1, 127-146
CrossRef97
Camilla Jandus, Daniel Speiser, Pedro Romero. (2009) Recent advances and hurdles in melanoma immunotherapy. Pigment Cell & Melanoma Research 22:6, 711-723
CrossRef98
Amir Khammari, Nathalie Labarrière, Virginie Vignard, Jean-Michel Nguyen, Marie-Christine Pandolfino, Anne C Knol, Gaëlle Quéreux, Soraya Saiagh, Anabelle Brocard, Francine Jotereau, Brigitte Dreno. (2009) Treatment of Metastatic Melanoma with Autologous Melan-A/Mart-1-Specific Cytotoxic T Lymphocyte Clones. Journal of Investigative Dermatology 129:12, 2835-2842
CrossRef99
Mark J. Dobrzanski, Kathleen A. Rewers-Felkins, Imelda S. Quinlin, Khaliquzzaman A. Samad, Catherine A. Phillips, William Robinson, David J. Dobrzanski, Stephen E. Wright. (2009) Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clinical Immunology 133:3, 333-352
CrossRef100
Michel Sadelain. (2009) T-Cell Engineering for Cancer Immunotherapy. The Cancer Journal 15:6, 451-455
CrossRef101
Otavia L. Caballero, Yao-Tseng Chen. (2009) Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Science 100:11, 2014-2021
CrossRef102
Khashayarsha Khazaie, Andreas Bonertz, Philipp Beckhove. (2009) Current developments with peptide-based human tumor vaccines. Current Opinion in Oncology 21:6, 524-530
CrossRef103
Markus Kapp, Leo Rasche, Hermann Einsele, Götz Ulrich Grigoleit. (2009) Cellular therapy to control tumor progression. Current Opinion in Hematology 16:6, 437-443
CrossRef104
Ninke Leffers, Annechien J.A. Lambeck, Marloes J.M. Gooden, Baukje-Nynke Hoogeboom, Rinze Wolf, Ineke E. Hamming, Bouke G. Hepkema, Pax H.B. Willemse, Barbara H.W. Molmans, Harry Hollema, Jan W. Drijfhout, Willem J. Sluiter, A. Rob P.M. Valentijn, Loraine M. Fathers, Jaap Oostendorp, Ate G.J. van der Zee, Cornelis J. Melief, Sjoerd H. van der Burg, Toos Daemen, Hans W. Nijman. (2009) Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer 125:9, 2104-2113
CrossRef105
Thomas M. Schmitt, Gunnar B. Ragnarsson, Philip D. Greenberg. (2009) T Cell Receptor Gene Therapy for Cancer. Human Gene Therapy 20:11, 1240-1248
CrossRef106
Y. Cui, H. Zhang, J. Meadors, R. Poon, M. Guimond, C. L. Mackall. (2009) Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 114:18, 3831-3840
CrossRef107
Michael Hudecek, Larry D Anderson Jr, Tetsuya Nishida, Stanley R Riddell. (2009) Adoptive T-cell therapy for B-cell malignancies. Expert Review of Hematology 2:5, 517-532
CrossRef108
Hanh K. Le, Laura Graham, Catriona H. T. Miller, Maciej Kmieciak, Masoud H. Manjili, Harry Douglas Bear. (2009) Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunology, Immunotherapy 58:10, 1565-1576
CrossRef109
Bei Wang, Janelle M.Y. Kuroiwa, Li-Zhen He, Anna Charalambous, Tibor Keler, Ralph M. Steinman. (2009) The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC-205/CD205 Receptor on Dendritic Cells. Annals of the New York Academy of Sciences 1174:1, 6-17
CrossRef110
John M. Grange, Bernd Krone, John L. Stanford. (2009) Immunotherapy for malignant melanoma – Tracing Ariadne’s thread through the labyrinth. European Journal of Cancer 45:13, 2266-2273
CrossRef111
W. Wang, R. Lau, D. Yu, W. Zhu, A. Korman, J. Weber. (2009) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells. International Immunology 21:9, 1065-1077
CrossRef112
Mario Sznol. (2009) Betting on immunotherapy for melanoma. Current Oncology Reports 11:5, 397-404
CrossRef113
Steven C. Katz, Venu Pillarisetty, Zubin M. Bamboat, Jinru Shia, Cyrus Hedvat, Mithat Gonen, William Jarnagin, Yuman Fong, Leslie Blumgart, Michael D’Angelica, Ronald P. DeMatteo. (2009) T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology 16:9, 2524-2530
CrossRef114
Yushe Dang, Mary L. Disis. (2009) Identification of Immunologic Biomarkers Associated with Clinical Response after Immune-Based Therapy for Cancer. Annals of the New York Academy of Sciences 1174:1, 81-87
CrossRef115
Antoine Tesniere, Guido Kroemer, Thomas Tursz, Laurence Zitvogel. (2009) Personalized immunotherapy: a siren myth?. Personalized Medicine 6:5, 469-473
CrossRef116
Neil L. Berinstein. (2009) Strategies to Enhance the Therapeutic Activity of Cancer Vaccines: Using Melanoma as a Model. Annals of the New York Academy of Sciences 1174:1, 107-117
CrossRef117
D. Schadendorf, S. M. Algarra, L. Bastholt, G. Cinat, B. Dreno, A. M. M. Eggermont, E. Espinosa, J. Guo, A. Hauschild, T. Petrella, J. Schachter, P. Hersey. (2009) Immunotherapy of distant metastatic disease. Annals of Oncology 20:Supplement 6, vi41-vi50
CrossRef118
Gabriel A. Kwong, Caius G. Radu, Kiwook Hwang, Chengyi J. Shu, Chao Ma, Richard C. Koya, Begonya Comin-Anduix, Sine Reker Hadrup, Ryan C. Bailey, Owen N. Witte, Ton N. Schumacher, Antoni Ribas, James R. Heath. (2009) Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells. Journal of the American Chemical Society 131:28, 9695-9703
CrossRef119
R. Geiger, T. Duhen, A. Lanzavecchia, F. Sallusto. (2009) Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. Journal of Experimental Medicine 206:7, 1525-1534
CrossRef120
Cristina Mastini, Cinzia Martinengo, Giorgio Inghirami, Roberto Chiarle. (2009) Anaplastic lymphoma kinase: an oncogene for tumor vaccination. Journal of Molecular Medicine 87:7, 669-677
CrossRef121
Zuqiang Liu, Shenghe Tian, Louis D Falo, Shimon Sakaguchi, Zhaoyang You. (2009) Therapeutic Immunity by Adoptive Tumor-primed CD4+ T-cell Transfer in Combination With In Vivo GITR Ligation. Molecular Therapy 17:7, 1274-1281
CrossRef122
Alexander M.M. Eggermont, Dirk Schadendorf. (2009) Melanoma and Immunotherapy. Hematology/Oncology Clinics of North America 23:3, 547-564
CrossRef123
Sheng Zhang, Dannie Bernard, Waliul I. Khan, Mark H. Kaplan, Jonathan L. Bramson, Yonghong Wan. (2009) CD4+ T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis. European Journal of Immunology 39:5, 1252-1259
CrossRef124
Lin Lin Liu, Myles J. Smith, Bao Sheng Sun, Guan Jun Wang, H. Paul Redmond, Jiang Huai Wang. (2009) Combined IFN-γ–Endostatin Gene Therapy and Radiotherapy Attenuates Primary Breast Tumor Growth and Lung Metastases via Enhanced CTL and NK Cell Activation and Attenuated Tumor Angiogenesis in a Murine Model. Annals of Surgical Oncology 16:5, 1403-1411
CrossRef125
Aaron S Mansfield, Svetomir N Markovic. (2009) Novel therapeutics for the treatment of metastatic melanoma. Future Oncology 5:4, 543-557
CrossRef126
A. Ziegler, R. Heidenreich, H. Braumuller, H. Wolburg, S. Weidemann, R. Mocikat, M. Rocken. (2009) EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 113:15, 3494-3502
CrossRef127
T Ohkuri, D Wakita, K Chamoto, Y Togashi, H Kitamura, T Nishimura. (2009) Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. British Journal of Cancer 100:7, 1135-1143
CrossRef128
Michael Dougan, Glenn Dranoff. (2009) Immune Therapy for Cancer. Annual Review of Immunology 27:1, 83-117
CrossRef129
Margret Wuttke, Claudia Papewalis, Benedikt Jacobs, Matthias Schott. (2009) Identifying tumor antigens in endocrine malignancies. Trends in Endocrinology & Metabolism 20:3, 122-129
CrossRef130
Myles Smith, Jiang Huai Wang, Thomas Cotter, Henry Redmond. (2009) Clinical Implications of the Mechanisms Driving Breast Cancer Local Recurrence. Annals of Surgical Oncology 16:3, 785-786
CrossRef131
Thomas Simon, Jean-François Fonteneau, Marc Grégoire. (2009) Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy 1:2, 289-302
CrossRef132
Daniel Hollyman, Jolanta Stefanski, Mark Przybylowski, Shirley Bartido, Oriana Borquez-Ojeda, Clare Taylor, Raymond Yeh, Vanessa Capacio, Malgorzata Olszewska, James Hosey, Michel Sadelain, Renier J. Brentjens, Isabelle Rivière. (2009) Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy. Journal of Immunotherapy 32:2, 169-180
CrossRef133
Sanaa El Marsafy, Martine Bagot, Armand Bensussan, Alain Mauviel. (2009) Dendritic cells in the skin - potential use for melanoma treatment. Pigment Cell & Melanoma Research 22:1, 30-41
CrossRef134
Kim Margolin. (2009) IL-2 in the therapy of melanoma and other malignancies. Medical Oncology 26:S1, 23-31
CrossRef135
Stephen E. Wright, Kathleen A. Rewers-Felkins, Imelda S. Quinlin, Catherine A. Phillips, Mary Townsend, Ramila Philip, Paul Zorsky, Panpit Klug, Lijun Dai, Mohammad Hussain, Aabu A. Thomas, Chithraleka Sundaramurthy. (2009) Tumor Burden Influences Cytotoxic T Cell Development in Metastatic Breast Cancer Patients—A Phase I/II Study. Immunological Investigations 38:8, 820-838
CrossRef136
Keyue Shen, Michael C Milone, Michael L. Dustin, Lance Cameron Kam. (2009) Nanoengineering of Immune Cell Function. MRS Proceedings 1209,
CrossRef137
(2008) Cellules T autologues contre mélanome M+. Revue Francophone des Laboratoires 2008:407, 21
CrossRef138
D. Wolf. (2008) Current status of immunotherapy for cancer treatment. memo - Magazine of European Medical Oncology 1:4, 190-192
CrossRef139
C. Robert. (2008) Quoi de neuf en cancérologie cutanée ?. Annales de Dermatologie et de Vénéréologie 135, S354-S359
CrossRef140
F Stephen Hodi, David E Fisher. (2008) Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nature Clinical Practice Oncology 5:12, 696-697
CrossRef141
K Kaluza, R G Vile. (2008) Magnetic cells for cancer therapy: Adopting magnets for cell-based cancer therapies. Gene Therapy 15:23, 1511-1512
CrossRef142
A COOSEMANS, P MOERMAN, G VERBIST, W MAES, P NEVEN, I VERGOTE, S VANGOOL, F AMANT. (2008) Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecologic Oncology 111:3, 502-508
CrossRef143
A. Boni, P. Muranski, L. Cassard, C. Wrzesinski, C. M. Paulos, D. C. Palmer, L. Gattinoni, C. S. Hinrichs, C.-C. Chan, S. A. Rosenberg, N. P. Restifo. (2008) Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 112:12, 4746-4754
CrossRef144
(2008) Editors' Picks. Journal of Investigative Dermatology 128:11, 2565-2565
CrossRef145
Martin A Pule, Barbara Savoldo, G Doug Myers, Claudia Rossig, Heidi V Russell, Gianpietro Dotti, M Helen Huls, Enli Liu, Adrian P Gee, Zhuyong Mei, Eric Yvon, Heidi L Weiss, Hao Liu, Cliona M Rooney, Helen E Heslop, Malcolm K Brenner. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine 14:11, 1264-1270
CrossRef146
(2008) Cancer Immunotherapy. New England Journal of Medicine 359:10, 1072-1073
Full Text147
Yin Hwa Lai, Chong Wang. (2008) Delivery strategies of melanoma vaccines: an overview. Expert Opinion on Drug Delivery 5:9, 979-1001
CrossRef148
Helen E Heslop, Malcolm K Brenner. (2008) The Clone Ranger?. Molecular Therapy 16:9, 1520-1521
CrossRef149
Lawrence G Lum, Zaid Al-Kadhimi. (2008) Development and prospects for bispecific antibody-based therapeutics in cancer and other applications. Expert Opinion on Drug Discovery 3:9, 1081-1097
CrossRef150
(2008) News in brief. Nature Medicine 14:8, 798-799
CrossRef151
Weiner, Louis M., . (2008) Cancer Immunotherapy — The Endgame Begins. New England Journal of Medicine 358:25, 2664-2665
Full Text
- Letters
